FTY720 May Treat Imatinib (Gleevec)- Resistant Leukemia
Filed in archive Drugs, Vaccines and Therapeutics on August 28, 2007

In a mouse model, scientists have demonstrated that treatment with a drug known as FTY720 prevents many leukemias caused by the cancer protein BCR-ABL- nearly all cases of blast crisis chronic myeloid leukemia and some cases of acute lymphocytic leukemia. These are fatal leukemias against which Abl kinase inhibitors such as imatinib (Gleevec) fail to induce a long-term response. FTY720 activates protein phosphatase 2A (PP2A), which is a tumor suppressor that is inactivated by signals induced by BCR-ABL.
Our data indicate that FTY720 induces apoptosis and impairs clonogenicity of imatinib/dasatinib-sensitive and -resistant p210/p190BCR/ABL myeloid and lymphoid cell lines and CML-BCCD34+ and Ph1 ALLCD34+/CD19+ progenitors but not of normal CD34+ and CD34+/CD19+ bone marrow cells. Furthermore, pharmacologic doses of FTY720 remarkably suppress in vivo p210/p190BCR/ABL-driven [including p210/p190BCR/ABL (T315I)] leukemogenesis without exerting any toxicity. Altogether, these results highlight the therapeutic relevance of rescuing PP2A tumor suppressor activity in Ph1 leukemias and strongly support the introduction of the PP2A activator FTY720 in the treatment of CML-BC and Ph1 ALL patients.
The pharmacologic doses of FTYY720 used to suppress leukemogenesis in the mice had no adverse effects and FTY720 has thus far shown no adverse effects in clinical trials testing its potential as a therapeutic for the treatment of multiple sclerosis. The study has been published online in the Journal of Clinical Investigation (doi: 10.1172/JCI31095).
Image: A Wright's stained bone marrow aspirate smear of patient with precursor B-cell acute lymphoblastic leukemia. Credit: VashiDonsk
Tags: leukemia ALL gleevec lymphocytic+leukemia myeloid+leukemia cancer biotech biotech+center
Vote for FTY720 May Treat Imatinib (Gleevec)- Resistant Leukemia:
|
Rating: 7.88 out of 8 vote(s) cast.
|
Most Popular
Best of
Biotech Hubs and Facilities
Biotech/Science Blogs
Corporate and Industrial News
Diagnostics, Methodologies and Instrumentation
Did you know
Drugs, Vaccines and Therapeutics
Energy, Environment and Ecology
Food and Agriculture
Gene Therapy
Genomics, Proteomics and Bioinformatics
Information About
Meetings and Other Events
Microbiology
Misc
Nanomedicine
Other Biotechnology News
Patents and Intellectual Property Rights
Quick introduction
Stem Cells
